Dear All,
After six emails I got a response from my MP ... nothing spectacular but nonetheless helpful. However, the apparent preference to depend on treatment rather than prevention is worrying.
"Thank you for your correspondence of 25 April on behalf of your constituent, about COVID-19 treatments.
I am grateful to you for raising his concerns.
Immunocompromised individuals are a priority group for research into therapeutic and prophylactic (preventative) treatments such as monoclonal antibody therapies, novel antivirals and repurposed compounds. Identifying effective new treatments is especially important for people who cannot take a vaccine for medical reasons, or for whom vaccines may be less effective.
The prophylactic monoclonal antibody treatment Evusheld is a mixture of tixagevimab and cilgavimab. It received a conditional marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) on 17 March.
However, the Evusheld trial took place before the emergence of the Omicron variant. This means there is not yet enough data to know how effective Evusheld is against Omicron, or the duration of any effects it may have against this variant. The MHRA will continue to work to establish this.
The UK Health Security Agency is also carrying out further testing on Evusheld’s effectiveness against this variant. The results of these tests will help inform any decisions on the next steps for this treatment, including procurement.
The RAPID C-19 collaboration has enabled multi-agency oversight of national and international trial evidence as it emerges for potential treatments and promising prophylactic therapies. This collaboration reviews all promising compounds to assess whether these should be considered for use in the NHS.
To date, the evidence has most strongly supported treatment rather than prophylaxis. The evidence on preventative therapies will continue to be reviewed to ensure efficacy and safety.
Non-hospitalised individuals who are in the highest risk group and receive a positive COVID-19 test result are able to access treatments. Eligible patients who receive a positive test result will be contacted by a clinician from a COVID Medicines Delivery Unit to discuss what treatments would be most suitable for them. This could be either sotrovimab or nirmatrelvir with ritonavir (Paxlovid), and those who are unable to receive these treatments will be offered remdesivir (Veklury) and then molnupiravir.
Further information on COVID-19 treatments, including monoclonal antibody and antiviral treatments, can be found at cas.mhra.gov.uk/help/corona....
I hope this reply is helpful.
LORD KAMALL